Wall Street analysts expect Seres Therapeutics Inc (NASDAQ:MCRB) to post $6.82 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Seres Therapeutics’ earnings. The highest sales estimate is $9.26 million and the lowest is $3.00 million. Seres Therapeutics reported sales of $10.63 million during the same quarter last year, which indicates a negative year over year growth rate of 35.8%. The company is scheduled to announce its next quarterly earnings results on Wednesday, March 4th.
On average, analysts expect that Seres Therapeutics will report full year sales of $34.21 million for the current financial year, with estimates ranging from $29.88 million to $36.14 million. For the next fiscal year, analysts forecast that the company will post sales of $32.51 million, with estimates ranging from $18.70 million to $43.83 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. The firm had revenue of $7.03 million for the quarter, compared to analysts’ expectations of $6.69 million.
MCRB has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 7th. Cowen restated a “buy” rating on shares of Seres Therapeutics in a research note on Monday, November 4th. ValuEngine upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Chardan Capital restated a “buy” rating on shares of Seres Therapeutics in a research note on Thursday, September 19th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $7.75.
MCRB stock traded up $0.15 during mid-day trading on Wednesday, reaching $3.87. 192,900 shares of the stock traded hands, compared to its average volume of 188,710. The stock’s fifty day moving average is $3.49 and its 200-day moving average is $3.51. The company has a market cap of $258.28 million, a P/E ratio of -1.59 and a beta of 1.78. Seres Therapeutics has a 52-week low of $2.02 and a 52-week high of $8.82.
Several institutional investors have recently made changes to their positions in MCRB. Tower Research Capital LLC TRC grew its stake in shares of Seres Therapeutics by 3,656.7% in the second quarter. Tower Research Capital LLC TRC now owns 8,678 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 8,447 shares during the last quarter. Aries Wealth Management bought a new position in Seres Therapeutics in the third quarter worth $31,000. SG Americas Securities LLC bought a new position in Seres Therapeutics in the second quarter worth $34,000. Parametric Portfolio Associates LLC bought a new position in Seres Therapeutics in the second quarter worth $42,000. Finally, A.R.T. Advisors LLC bought a new position in Seres Therapeutics in the second quarter worth $64,000. Institutional investors and hedge funds own 95.89% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
See Also: Cash Asset Ratio
Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
